Maze Therapeutics shares reportedly jump 22% after Vertex kidney drug results
Barron’s says Vertex Pharmaceuticals’ reported positive results for inaxaplin boosted confidence in a rival treatment from Maze Therapeutics.
TLDR
Barron’s reports that Maze Therapeutics stock jumped 22% after Vertex Pharmaceuticals reported positive results for its kidney drug inaxaplin. The news boosted confidence in Maze’s rival treatment, the outlet says.
Combined views
4.6K
1 Source, first seen 8d ago
5 likes1 saves1 reposts